Annalisa has over 20 years of experience in drug development within the academic, government, and industry environments. At Evidera she works in the Real-World Evidence group, providing expertise in observational studies and therapeutic risk management, including post-authorization safety studies (PASS) and risk minimization interventions.
Before joining Evidera, Annalisa worked in the consultancy sector on complex drug safety studies and overall safety strategies for risk management purposes. From 2010 to 2015 Annalisa was a scientific administrator at the European Medicines Agency (EMA), leading the development of guidelines on therapeutic risk minimization. In her earlier academic career, she was a principal investigator at the University College London (UK), where she was awarded several prestigious fellowships and grants.
Annalisa has published more than 50 peer-reviewed articles, including papers on high impact journals (e.g., BMJ, Trends in Pharmacological Sciences), and is an experienced speaker at international conferences.
Annalisa holds a PhD in pharmacology from the University of Florence (Italy) and a master’s degree in epidemiology from the London School of Hygiene and Tropical Medicine, London (UK).